Do you or someone you know want to participate in a clinical study? See information for patients and families.

Support Materials


Protocol Registration and Results System (PRS) Information

Data Elements

Protocol Data Element Definitions: Describes the registration data items (required and optional) that are entered via PRS

Basic Results Data Element Definitions: Describes the results data items (required and optional) that are entered via PRS

Simple Results Templates and Results Data Preparation Checklists: Templates are a single-page formatted summary of the relevant data elements for each results module and the checklists provide an overview of the data needed. The templates and checklists are intended to help investigators understand and gather the data needed to complete each results module.

Review Criteria and Other Support Materials Protocol Review Criteria (PDF): Describes review criteria for study records submitted to the registry (Draft, August 2010) Results Review Criteria (PDF): Describes review criteria for each scientific module in the results section of the study record submitted to the results database (Draft, September 2009)

Helpful Hints (PDF): Tips on entering results data, including three examples of common study models (parallel design, crossover design, and diagnostic accuracy studies), and measure types (Draft, September 2009)

Registering and Reporting Results with (PDF): Trifold brochure providing an overview of key information on registering and submitting the results of clinical trials on (November 2009)

U.S. Laws, Regulations, and Guidance

NIH Draft Policy on Registration and Results Submission of NIH-Funded Trials

The US National Institutes of Health (NIH) proposed a policy to ensure that every clinical trial that receives NIH dollars is registered on and has summary results submitted and posted in a timely manner. For additional information on the NIH Draft Policy, see History, Policies, and Laws on

Food and Drug Administration Amendments Act of 2007 (FDAAA)

Section 801 of FDAAA (PDF) expanded the requirements for submitting clinical trial information to the database. The US Department of Health and Human Services (HHS) subsequently issued a notice of proposed rulemaking (NPRM) describing the proposed procedures for registering and submitting the results, including adverse events, of clinical trials on, in accordance with FDAAA 801. The NPRM does not change the current requirements; instead it is a proposal that is being issued for public comment to inform any future changes to requirements that will be implemented in a final rule. For additional information on the FDAAA 801 NPRM, see History, Policies, and Laws on

National Cancer Institute (NCI) Clinical Trial Access Policy

NCI issued its Policy Ensuring Public Availability of Results from NCI-supported Clinical Trials. NCI expects Final Trial Results for all NCI-supported Covered Trials to be reported in a publicly accessible manner within twelve (12) months of the Trial's Primary Completion Date.

Center for Medicare and Medicaid Services (CMS)

CMS issued a National Coverage Determination (NCD) for Routine Costs in Clinical Trials, Section 310.1 (July 2007). Claims for routine costs of qualifying clinical trials as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials covered by Medicare will require health care providers and suppliers to report a Identifier (NCT Number).

Food and Drug Administration Modernization Act of 1997 (FDAMA)

Section 113 of FDAMA mandated the creation of a clinical trials database to register clinical trials of investigational drugs for "serious or life-threating diseases and conditions" (November 1997).

International Policies

International Committee of Medical Journal Editors (ICMJE)

ICMJE issued a Clinical Trial Registration policy as part of the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals , which is followed by more than 1,000 journals. The ICMJE Recommendations encourage journal editors to require that all clinical trials be entered in a public registry before the start of participant enrollment in order for the trials to be considered for publication.

World Health Organization (WHO)

The WHO International Clinical Trials Registry Platform (ICTRP) policy specifies that "the registration of all interventional trials is a scientific, ethical and moral responsibility." Accordingly, the ICTRP provides a global forum for trial registries to share best practices and promotes the development of specific criteria for primary registries in the WHO Registry Network. In addition, the WHO Statement on the Public Disclosure of Clinical Trials Results specifies that "[t]here is an ethical imperative to report the results of all clinical trials, including those of unreported trials conducted in the past."

  • WHO ICTRP Trial Registration Data Set: Describes the minimum amount of trial information that must appear in a clinical study registry in order for a given trial to be considered fully registered by the WHO
  • WHO ICTRP Search Portal: Provides a single point of access to studies registered in various international registries, including data available on
This page last reviewed in September 2015